Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:05:24.024Z.
Calculation as of: 2026-10-06T12:05:24.024Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8d554412806125b06490580232e6d80b3120c6a72214b764814008bb1d876b03
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Ainos, Inc.
Market Cap
$9.79M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Ainos, Inc. (AIMD) | $9.79M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.27M | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.74M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.76M | N/A |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.37M | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.41M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
